Cerebroprotective effects of a novel pyrazoline derivative, MS-153, on focal ischemia in rats

Japanese Journal of Pharmacology
H KawazuraA Tamura

Abstract

MS-153 ((R)-(-)-5-methyl-1-nicotinoyl-2-pyrazoline) is a novel pyrazoline compound that has potent cerebroprotective effects in the rat focal cerebral ischemia model. Middle cerebral artery (MCA) occlusion in rats allows detailed assessment of both functional and morphological sequelae of brain infarct. Using this model, we evaluated the cerebroprotective effects of MS-153. Treatment with MS-153 (12.5 mg/kg, i.v. bolus followed by 6.25 mg/kg/hr or 25.0 mg/kg, i.v. bolus followed by 12.5 mg/kg/hr infusion for 7 days) significantly reduced infarct volumes and improved neurological deficits in MCA occluded rats 7 days after occlusion. Delayed treatment significantly reduced infarct volume 24 hr after MCA occlusion when MS-153 (25.0 mg/kg, i.v. bolus followed by 12.5 mg/kg/hr infusion for 21 hr) administration was started 3 hr after occlusion. Brain edema was also significantly improved when MS-153 (25.0 mg/kg, i.v. bolus followed by 12.5 mg/kg/hr infusion for 18 hr) administration was started 6 hr after occlusion.

Citations

Dec 9, 2010·Chemical & Pharmaceutical Bulletin·Cherkupally Sanjeeva ReddyAdki Nagaraj
Jun 24, 2004·Brain Research. Brain Research Reviews·Yasushi ShigeriKeiko Shimamoto
Jun 23, 2015·Journal of Neurochemistry·Andréia C K Fontana
Nov 21, 2009·European Journal of Medicinal Chemistry·Anjani SolankeeAthina Geronikaki
Feb 11, 2000·Annals of the New York Academy of Sciences·H UenishiT Narahashi
Jan 5, 2000·European Journal of Pharmacology·F ShimadaN Saito

❮ Previous
Next ❯

Related Concepts

Related Feeds

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.